Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status
J. Thorac. Oncol., Volume 15, Issue 11, November 2020, Pages 1758-1766 | https://doi.org/10.1016/j.jtho.2020.06.018